ICML 2019 | ViPOR regimen for R/R B-cell lymphoma

Wyndham Wilson

The Phase Ib study of venetoclax, ibrutinib, prednisone, obinutuzumab and lenalidomide (ViPOR) for relapsed/refractory B-cell lymphoma was presented at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, Wyndham Wilson, MD, PhD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, explains the safety, efficacy and molecular analysis results.

Share this video